Researchers from Johns Hopkins, Delfi Diagnostics and collaborators demonstrated that cfDNA fragmentomics can detect liver diseases such as cirrhosis and fibrosis from plasma samples, extending liquid‑biopsy applications beyond oncology. The pilot work showed organ‑specific fragmentation patterns and immune‑related signals that distinguished disease states. Separately, Peking University teams published cf‑EpiTracing, an automated chromatin‑centric cfDNA method that profiles histone modifications to predict tissues and cell types of origin for diverse diseases. The Nature paper distilled minimal histone mark combinations (H3K9ac, H3K27ac, H3K4me3) that retained tissue‑prediction accuracy across >2,400 plasma samples. Both efforts leverage non‑invasive blood assays to map tissue injury and disease biology and suggest parallel commercial paths: fragmentomics for pattern‑based diagnostics and cf‑epigenomics for tissue‑of‑origin resolution and molecular subtyping. For translational teams: these technologies may enable surveillance tests for non‑cancer conditions, inform patient selection for trials, and create new endpoints for drug development across liver, cardiac and inflammatory diseases.